Literature DB >> 25610076

Hemolytic activities of the Candida species in liquid medium.

Hilal Kuzucu Malcok1, Esin Aktas1, Ahmet Ayyildiz1, Nimet Yigit2, Halil Yazgi1.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the in vitro hemolytic activities of 107 Candida strains isolated from different clinical samples in liquid medium, and to examine the impact of glucose on this activity.
MATERIALS AND METHODS: A total of 107 Candida isolates representing seven species (C. albicans, n=28; C. glabrata, n=23; C. tropicalis, n=17; C. parapsilosis, n=16; C. kefyr, n=14; C. krusei, n=5; C. guilliermondii, n=4) were included in the study. The hemolytic activities of the strains were tested on two different Sabouraud dextrose liquid media (SDB) containing 7% defibrinated human blood, one of which is supplemented with 3% glucose and the other without glucose. Cultures were evaluated at the end of a 48-hour incubation. The hemolysis in the media was detected spectrophotometrically by measuring the amount of released hemoglobin and compared with a standard hemolysate which was prepared prior to testing. The degree of hemolysis (percentage value) by an individual strain was calculated according to the following formula below: (Absorbance of supernatant media at 540 nm / Absorbance of standard hemolysate at 540 nm X 100).
RESULTS: In the liquid medium without glucose, strains generally produced hemolysis at low levels. The degree of hemolysis produced by all species increased noticeably in the liquid medium with glucose. Strains of C. albicans and C.kefyr had demonstrated significant hemolytic activity, whereas others had lower activity. C. parapsilosis exerted very little hemolytic activity in the medium with glucose and showed no activity in the medium without glucose.
CONCLUSION: The hemolytic activities of most Candida species was found to be higher in the human blood-enriched SDB medium containing 3% additive glucose than in the one free from additives. This result indicates that increased blood glucose concentration may contribute to increased hemolytic activity in Candida species, and it suggests a parallel with possible pathogenesis of Candida in patients with diabetes mellitus.

Entities:  

Keywords:  Candida species; Hemolytic activity; Human blood saboraud dextrose broth

Year:  2009        PMID: 25610076      PMCID: PMC4299835     

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  15 in total

1.  Optically active antifungal azoles. XII. Synthesis and antifungal activity of the water-soluble prodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone.

Authors:  T Ichikawa; T Kitazaki; Y Matsushita; M Yamada; R Hayashi; M Yamaguchi; Y Kiyota; K Okonogi; K Itoh
Journal:  Chem Pharm Bull (Tokyo)       Date:  2001-09       Impact factor: 1.645

2.  Phenotypic switching in Candida glabrata involves phase-specific regulation of the metallothionein gene MT-II and the newly discovered hemolysin gene HLP.

Authors:  S A Lachke; T Srikantha; L K Tsai; K Daniels; D R Soll
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 3.  Biofilm lifestyle of Candida: a mini review.

Authors:  C J Seneviratne; L Jin; L P Samaranayake
Journal:  Oral Dis       Date:  2008-10       Impact factor: 3.511

Review 4.  Hydrolytic enzymes as virulence factors of Candida albicans.

Authors:  Martin Schaller; Claudia Borelli; Hans C Korting; Bernhard Hube
Journal:  Mycoses       Date:  2005-11       Impact factor: 4.377

5.  Enzymatic and hemolytic activities of Candida dubliniensis strains.

Authors:  Carlos Eduardo Blanco Linares; Erico Silva de Loreto; Carolina Pereira Silveira; Patrícia Pozzatti; Liliane Alves Scheid; Janio M Santurio; Sydney Hartz Alves
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2007 Jul-Aug       Impact factor: 1.846

6.  Expression of plasma coagulase among pathogenic Candida species.

Authors:  Acácio Gonçalves Rodrigues; Cidália Pina-Vaz; Sofia Costa-de-Oliveira; Christina Tavares
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

7.  Fungicidal effect of three new synthetic cationic peptides against Candida albicans.

Authors:  H Nikawa; H Fukushima; S Makihira; T Hamada; L P Samaranayake
Journal:  Oral Dis       Date:  2004-07       Impact factor: 3.511

8.  Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus.

Authors:  C S P Tsang; F C S Chu; W K Leung; L J Jin; L P Samaranayake; S C Siu
Journal:  J Med Microbiol       Date:  2007-10       Impact factor: 2.472

9.  Production of a hemolytic factor by Candida albicans.

Authors:  J M Manns; D M Mosser; H R Buckley
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Evidence implicating phospholipase as a virulence factor of Candida albicans.

Authors:  A S Ibrahim; F Mirbod; S G Filler; Y Banno; G T Cole; Y Kitajima; J E Edwards; Y Nozawa; M A Ghannoum
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more
  10 in total

Review 1.  How much do we know about hemolytic capability of pathogenic Candida species?

Authors:  Márcia C Furlaneto; Helena P Góes; Hugo F Perini; Renan C Dos Santos; Luciana Furlaneto-Maia
Journal:  Folia Microbiol (Praha)       Date:  2018-01-15       Impact factor: 2.099

2.  Partial characteristics of hemolytic factors secreted from airborne Aspergillus and Penicillium, and an enhancement of hemolysis by Aspergillus micronesiensis CAMP-like factor via Staphylococcus aureus-sphingomyelinase.

Authors:  Sumonrat Kaveemongkonrat; Kwanjit Duangsonk; Jos Houbraken; Phimchat Suwannaphong; Nongnuch Vanittanakom; Malee Mekaprateep
Journal:  J Microbiol       Date:  2019-11-04       Impact factor: 3.422

3.  Heme Oxygenase-1 (HMX1) Loss of Function Increases the In-Host Fitness of the Saccharomyces 'boulardii' Probiotic Yeast in a Mouse Fungemia Model.

Authors:  Alexandra Imre; Renátó Kovács; Zoltán Tóth; László Majoros; Zsigmond Benkő; Walter P Pfliegler; István Pócsi
Journal:  J Fungi (Basel)       Date:  2022-05-18

Review 4.  State of the Art in the Culture of the Human Microbiota: New Interests and Strategies.

Authors:  Maryam Tidjani Alou; Sabrina Naud; Saber Khelaifia; Marion Bonnet; Jean-Christophe Lagier; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2020-10-28       Impact factor: 26.132

5.  Effects of human blood red cells on the haemolytic capability of clinical isolates of Candida tropicalis.

Authors:  Marcia Cristina Furlaneto; Daniel Favero; Emanuele Julio Galvão França; Luciana Furlaneto-Maia
Journal:  J Biomed Sci       Date:  2015-02-11       Impact factor: 8.410

6.  The Fungal Pathogen Candida glabrata Does Not Depend on Surface Ferric Reductases for Iron Acquisition.

Authors:  Franziska Gerwien; Abu Safyan; Stephanie Wisgott; Sascha Brunke; Lydia Kasper; Bernhard Hube
Journal:  Front Microbiol       Date:  2017-06-08       Impact factor: 5.640

7.  Evaluation of esterase and hemolysin activities of different Candida species isolated from vulvovaginitis cases in Lorestan Province, Iran.

Authors:  Maryam Noori; Mohammad Dakhili; Asghar Sepahvand; Nader Davari
Journal:  Curr Med Mycol       Date:  2017-12

8.  In vitro antifungal activity of Cinnamomum zeylanicum bark and leaf essential oils against Candida albicans and Candida auris.

Authors:  Hoang N H Tran; Lee Graham; Emmanuel C Adukwu
Journal:  Appl Microbiol Biotechnol       Date:  2020-09-03       Impact factor: 4.813

Review 9.  COVID-19-Associated Candidiasis: Possible Patho-Mechanism, Predisposing Factors, and Prevention Strategies.

Authors:  Nafisa Ahmed; Maiesha Samiha Mahmood; Md Asad Ullah; Yusha Araf; Tanjim Ishraq Rahaman; Abu Tayab Moin; Mohammad Jakir Hosen
Journal:  Curr Microbiol       Date:  2022-03-14       Impact factor: 2.343

10.  Therapeutic Significance of Loligo vulgaris (Lamarck, 1798) ink Extract: A Biomedical Approach.

Authors:  Sri Kumaran Nadarajah; Radha Vijayaraj; Jayaprakashvel Mani
Journal:  Pharmacognosy Res       Date:  2017-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.